Compare MATH & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | CGEN |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | MATH | CGEN |
|---|---|---|
| Price | $2.45 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 46.5K | ★ 437.5K |
| Earning Date | 03-06-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $1.25 | $1.13 |
| 52 Week High | $4.17 | $2.66 |
| Indicator | MATH | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 65.73 |
| Support Level | $2.28 | $1.43 |
| Resistance Level | $2.50 | $1.73 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 82.33 | 91.67 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.